tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Freedman RB Immunosuppression. Convergence of drug action. 1989 Nature pmid:2477712
Siekierka JJ et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. 1989 Nature pmid:2477714
Harding MW et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 1989 Nature pmid:2477715
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
Starzl TE et al. FK 506 for liver, kidney, and pancreas transplantation. 1989 Lancet pmid:2478846
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Yamamoto K et al. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. 1990 Immunology pmid:1689694
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Mieles L et al. Oral glucose tolerance test in liver recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689894
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Suzuki N et al. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. 1990 Clin. Exp. Immunol. pmid:1690097
McCauley J et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. 1990 Lancet pmid:1690326
Hoffman AL et al. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. 1990 Transplantation pmid:1690469
Woo J et al. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. 1990 Scand. J. Immunol. pmid:1690915
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Harrison RK and Stein RL Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. 1990 Biochemistry pmid:1693856
Starzl TE et al. Kidney transplantation under FK 506. 1990 JAMA pmid:1693970
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Deguchi K et al. [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. 1990 No To Shinkei pmid:1697182
Murase N et al. Prevention of spontaneous diabetes in BB rats with FK 506. 1990 Lancet pmid:1697397
Justice RM et al. The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. 1990 Biochem. Biophys. Res. Commun. pmid:1697463
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Kawashima H and Mochizuki M Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. 1990 Exp. Eye Res. pmid:1701148
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Arita C et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. 1990 Clin. Exp. Immunol. pmid:1702374
Woo J et al. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. 1990 Clin. Exp. Immunol. pmid:1702375
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242